---
schema_version: "secwatch.filing_event.v1"
accession: "0001628171-26-000004"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2026-10-13T20:32:09+00:00"
generated_at: "2026-10-13T20:33:03.221793+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines draws $250M Tranche A loan after FDA approves RASONQUE for pancreatic cancer

## Summary
- Tranche A Loan of $250.0M funded Oct 8, 2026, triggered by FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy.
- Interest at 3-month Term SOFR, floor of 3.50%, plus 5.75%, payable quarterly in arrears; interest-only with principal due Oct 8, 2032.
- Company paid Royalty Pharma a $5.0M draw fee; up to $500.0M more available under the $750.0M senior secured facility subject to milestones.
- Prepayment terms: make-whole plus 3.0% premium before the 2nd anniversary, 3.0% before the 3rd, and 1.0% thereafter.
- Company elected not to deliver a Tranche 3 Notice by the Oct 10, 2026 deadline, forgoing up to $250.0M and selling no incremental revenue participation right.

## SEC filing metadata
- accession: 0001628171-26-000004
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2026-10-13T20:32:09+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.03, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000162817126000004/0001628171-26-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000162817126000004/rvmd-20261008.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628171-26-000004
- JSON: https://secwatch.observer/filing/0001628171-26-000004.json
- Plain text: https://secwatch.observer/filing/0001628171-26-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.